Significant risk of arthrolysis after simultaneous anterior cruciate ligament reconstruction and treatment of dislocated bucket-handle meniscal tear

INTRODUCTION: Postoperative stiffness is a feared complication after anterior cruciate ligament (ACL) reconstruction. In case of associated dislocated bucket-handle meniscal tear (BHMT), reduction is urgent, with ligament reconstruction in the same surgical step.HYPOTHESIS: Treatment of associated dislocated BHMT in ACL reconstruction incurs increased risk of arthrolysis for stiffness in flexion and/or extension.MATERIAL AND METHODS: A retrospective exposure/non-exposure study included 208 patients undergoing ACL reconstruction between January 2009 and December 2018. Those showing dislocated medial or lateral BHMT at surgery (group A) were compared versus those free of meniscal lesions (group B). The main objective was to assess the risk of surgical revision for arthrolysis within 12 months. Group A included 69 patients: 40 male (58%), 29 female (42%); mean age, 29.0±11.2 years. Group B included 139 patients: 68 male (49%), 71 female (51%); mean age, 30.0±10.4 years. Patients were classified according to age of ACL tear, as acute (6 months).RESULTS: Risk of revision surgery for arthrolysis was greater in Group A than in Group B, with 7 (10.1%) and 4 (2.9%) cases respectively (p=0.044), with 12-month arthrolysis-free survival of 89.7% (95% CI, 82.7-97.2) and 97.1% (95% CI, 94.3-99.9) respectively (p=0.023). Stiffness in flexion and extension was more frequent in Group A at 6 weeks and at 6 months (p>0.05). Risk of arthrolysis did not significantly differ according to accident-to-surgery time in the overall series (p=0.421) or specifically in Group A (p=0.887). The BHMT was sutured in 39 cases (56.5%), including 3 failures (7.7%) at 12 months' follow-up. Arthrolysis was required in 6 patients treated by meniscal suture (15.4%) and just 1 patient treated by meniscectomy (3.3%) (p=0.128).CONCLUSION: The present study confirmed increased risk of surgical revision for arthrolysis after ACL reconstruction in case of dislocated BHMT treated in the same surgical step. Age of ACL tear and type of BHMT treatment (suture or meniscectomy) showed no impact on postoperative stiffness.LEVEL OF EVIDENCE: IV, retrospective exposure/non-exposure cohort study

No clinical difference at mid-term follow-up between TiN-coated versus uncoated cemented mobile-bearing total knee arthroplasty: a matched cohort study

Introduction: Nitride-based ceramic coating was introduced into surgical implants to improve hardness, reduce abrasion, and decrease the risk of metal-induced adverse reactions, especially for patients with suspected or identified metal hypersensitivity. The study aimed to evaluate the effectiveness and safety of a titanium nitride (TiN) coated prosthesis with a mobile bearing design. Methods: This was a retrospective matched-cohort study from a single center, comparing clinical outcomes between patients receiving either a TiN-coated versus an uncoated cobalt-chromium-molybdenum (CoCrMo) prostheses for primary total knee replacement. Seventeen patients received the TiN prosthesis between 2015 and 2019. These were matched 1:2 with patients receiving uncoated mobile-bearing knee prostheses with the same design manufacturer. Results: Fourteen patients in the TiN group had complete 5-year follow-up data and were compared with 34 patients from the CoCrMo group. The Knee Society Score was 170.6 ± 28.0 (Function subscore 83.7 ± 17.5 and Knee subscore 86.9 ± 13.8) in the TiN group and 180.7 ± 49.4 (Function subscore 87.5 ± 14.3 and Knee subscore 93.2 ± 9.6) in CoCrMo group, with no statistically significant difference (p = 0.19). One patient underwent a revision for instability requiring the removal of the implant in the TiN group and none in the CoCrMo group. The survival rates were 92.9% (CI95% 77.3–100.0) and 100.0% in the TiN group and CoCrMo group respectively (p = 1.0). Discussion: TiN-coated TKA with mobile bearing resulted in satisfactory clinical outcomes, and a low revision rate, and there was no complication related to the coated implant. The use of TiN-coated prostheses in case of confirmed or suspected metal allergy provides satisfactory short-term clinic outcomes

High Survival Rate and Very Low Wear of Lateral Unicompartmental Arthroplasty at Long Term

International audienceBackgroundSurvivorship of lateral unicompartmental knee arthroplasty (UKA) has progressively improved. However, there are few studies describing long-term results, and no study reports on polyethylene (PE) wear in lateral unicompartmental arthroplasty. The aims of this study are to determine the survival rate of lateral UKA with a fixed, all-PE bearing, and the PE wear of the tibial implant at a minimum of 15 years follow-up.MethodsFrom January 1988 to October 2003, we performed 54 lateral UKAs in 52 patients. All patients had isolated lateral osteoarthritis (OA). The mean age at the index procedure was 65.4 ± 11 years. Thirty-nine UKAs were available for follow-up (30 alive and 9 dead after 15 years). Twelve patients had died before 15 years and 3 patients were lost to follow-up. The mean follow-up was 17.9 years (range, 15-23 years).ResultsAt the final follow-up, 8 knees of 39 (20.5%) had a surgical revision. The cumulative survival rate was 82.1% at 15 years and 79.4% at 20 years. The main reason of revision was progression of OA (87.5%), followed by aseptic loosening of the tibial component (12.5%). With a mean follow-up of 17.9 years, the mean PE wear was 0.061 mm/y. There was no radiographic loosening in the surviving implants and no revisions for wear. The mean functional International Knee Society score was 66.5 ± 26.8, with a mean objective score of 84.4 points ± 13.2. In the population without revision, 90.5% were satisfied or very satisfied at the latest follow-up.ConclusionLateral UKA with a fixed, all-PE tibial bearing and a femoral resurfacing implant presents a high survivorship at long term, with very low PE wear

Similar survival rate but lower functional outcomes following TKA in the elderly people compared to younger patients: analysis of a posterior stabilised implant with minimum 5-year follow-up

BACKGROUND: Literature regarding outcomes in patients over 80years old after total knee arthroplasty (TKA) is inconsistent. We aimed to compare implant survivorship and functional outcomes between elderly patients (??80years) and younger patients (?0.05), nor regarding maximum flexion (121°?±?12 and 117°?±?13, p?=?0.08). The implant survivorship was 100.0% after a mean 64.4-month follow-up (range 60-78), without revision requiring removal of the implant in any group. The survival rate without any reoperation was 97.6% (95% CI 93.0-100.0) in the elderly group and 95.9% (95% CI 92.5-99.5) in the younger group (p?=?0.64).CONCLUSION: At a minimum of 5-year follow-up, there was no revision surgery and a very low rate of complications requiring reoperations both in the group over 80years of age and in the younger population, with the use of a PS prosthesis. The functional results were slightly lower for elderly patients and correlate with the lower functional demands of this population. The indication for TKA, especially with a PS implant, may be encouraged in appropriately selected elderly patients.LEVEL OF EVIDENCE: III (retrospective cohort study)

Is Cemented Dual-Mobility Cup a Reliable Option in Primary and Revision Total Hip Arthroplasty: A Systematic Review

Background: Instability is a common complication following total hip arthroplasty (THA). The dual mobility cup (DMC) allows a reduction in the dislocation rate. The goal of this systematic review was to clarify the different uses and outcomes according to the indications of the cemented DMC (C-DMC). Methods: A systematic review was performed using the keywords “Cemented Dual Mobility Cup” or “Cemented Tripolar Cup” without a publication year limit. Of the 465 studies identified, only 56 were eligible for the study. Results: The overall number of C-DMC was 3452 in 3426 patients. The mean follow-up was 45.9 months (range 12–98.4). In most of the cases (74.5%) C-DMC was used in a revision setting. In 57.5% DMC was cemented directly into the bone, in 39.6% into an acetabular reinforcement and in 3.2% into a pre-existing cup. The overall dislocation rate was 2.9%. The most frequent postoperative complications were periprosthetic infections (2%); aseptic loosening (1.1%) and mechanical failure (0.5%). The overall revision rate was 4.4%. The average survival rate of C-DMC at the last follow-up was 93.5%. Conclusions: C-DMC represents an effective treatment option to limit the risk of dislocations and complications for both primary and revision surgery. C-DMC has good clinical outcomes and a low complication rate

No difference between resurfaced and non-resurfaced patellae with a modern prosthesis design: a prospective randomized study of 250 total knee arthroplasties

PURPOSE: Despite numerous well-conducted studies and meta-analyses, the management of the patella during total knee arthroplasty (TKA) remains controversial. The aim of our study was to compare the clinical and radiological outcomes between patients with and without patellar resurfacing and to determine the influence of resurfacing on patellar tracking with a "patella-friendly" prosthesis.METHODS: A single-centered prospective randomized controlled study was performed between April 2017 and November 2018. Two hundred and forty-five consecutive patients (250 knees) scheduled for TKA were randomized for patellar resurfacing or patella non-resurfacing. All patients received the same total knee prosthesis and were evaluated clinically and radiologically, including the International Knee Society Score (KSS knee and function), Forgotten Joint Score (FJS), anterior knee pain (AKP), pain when climbing stairs, patellar tilt, and patellar translation.RESULTS: Two hundred and twenty-nine knees were available for clinical evaluation and 221 knees for radiographic analysis. The revision rate for patellofemoral cause was 3.1% (7 cases) with no difference between the groups (p?=?0.217). There was no difference in survival rate between patellar resurfacing (88.3%) and non-resurfacing (85.3%) after 24months (p?=?0.599). There were no differences in KSS functional component (p?=?0.599), KSS knee component (p?=?0.396), FJS (p?=?0.798), and AKP (p?=?0.688) at a mean follow-up of 18months. There was twice as much stair pain for the non-resurfacing group (17.1% versus 8.5%) (p?=?0.043). There was patellar tilt in 43% of resurfaced knees (n?=?50/116) versus 29% in non-resurfaced knees (n?=?30/105) (p?=?0.025); however, there was more patellar translation in the non-resurfaced group (21.0% versus 7.8%) (p

Femorotibial alignment measured during robotic assisted knee surgery is reliable: radiologic and gait analysis

Femorotibial alignment is crucial for the outcome of unicompartmental knee arthroplasty (UKA). Robotic-assisted systems are useful to increase the accuracy of alignment in UKA. However, no study has assessed if the femorotibial alignment measured by the image-free robotic system is reliable. The aim of this study was to determine whether measurement of the mechanical femorotibial axis (mFTA) in the coronal plane with handheld robotic assistance during surgery is equivalent to a static measurement on radiographs and to a dynamic measurement during walking

Excellent outcomes for lateral unicompartmental knee arthroplasty: Multicenter 268-case series at 5 to 23 years' follow-up

Introduction: Isolated lateral compartment osteoarthritis of the knee (LCOA) is 10 times less frequent than medial compartment involvement. Long-term assessments of unicompartmental knee arthroplasty (UKA) in this indication are rare, with small series. Hypothesis Survival and functional outcome of lateral UKA in a large series are quite acceptable; the strategy is suited for isolated LCOA. Material and method A multicenter retrospective study in 6 French health establishments included all lateral UKAs performed between January 1988 and September 2014. Clinical data (range of motion, International Knee Society (IKS) knee and function scores, satisfaction), paraclinical data (radiologic angles) and complications were prospectively entered in medical files during follow-up and analyzed retrospectively at end of follow-up. Results During the study period, 311 lateral UKAs were performed in 295 patients, using 5 fixed-bearing implant models. Twenty-eight patients died within 5 years, and 15 (4.8%) were lost to follow-up. The series thus comprised 268 lateral UKAs in 63 male and 205 female patients, with a mean age of 68.8±10.5 years, including 7 cases of post-traumatic osteoarthritis and 4 of aseptic osteonecrosis. Mean follow-up was 9.1 years (range, 5-23 years), implant survivorship with failure defined as all-cause revision surgery was 85.4% at 10 years and 79.4% at 20 years. At last follow-up, IKS knee score was 87.0 and IKS function score 80.2. Maximal flexion was 125°. 94.3% of patients were satisfied or very satisfied. The main cause of revision surgery was osteoarthritis in another knee compartment (66,7%, n=26). Conclusion: Lateral UKA showed good survivorship, comparable to medial UKA, with good functional results and excellent long-term satisfaction. Level of evidence IV, retrospective cohort study

Pregnenolone can protect the brain from cannabis intoxication

Pregnenolone is considered the inactive precursor of all steroid hormones, and its potential functional effects have been largely uninvestigated. The administration of the main active principle of Cannabis sativa (marijuana), Δ(9)-tetrahydrocannabinol (THC), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (CB1) receptor. Pregnenolone then, acting as a signaling-specific inhibitor of the CB1 receptor, reduces several effects of THC. This negative feedback mediated by pregnenolone reveals a previously unknown paracrine/autocrine loop protecting the brain from CB1 receptor overactivation that could open an unforeseen approach for the treatment of cannabis intoxication and addiction.Supported by the EU-FP7 (REPROBESITY, HEALTH-F2-2008-223713, G.M.), the European Research Council (ENDOFOOD, ERC-2010-StG-260515, G.M.), the Agence Nationale pour la Recherche (contracts HICOMET and TIMMS, P.V.P.), the U.S. National Institutes of Health (NIH) (grants DA-03672, DA-003934, and DA-09789, R.A.R. and G.L.B., and RO1 DA003934 and KO5 DA021358, P.H.R